GlaxoSmithKline is a drug manufacturers - general business based in the US. GlaxoSmithKline shares (GSK.US) are listed on the NYSE and all prices are listed in US dollars. Its last market close was $41.11 – an increase of 0.49% over the previous day. GlaxoSmithKline employs 70,212 staff and has a trailing 12-month revenue of around $30.3 billion.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $32.3451 up to $43.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.268. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $41.11
| 1 week (2024-04-18) | 3.42% |
|---|---|
| 1 month (2024-03-27) | -4.11% |
| 3 months (2024-01-25) | 5.22% |
| 6 months (2023-10-26) | 18.95% |
| 1 year (2023-04-27) | 14.10% |
| 2 years (2022-04-27) | -10.12% |
| 3 years (2021-04-27) | 9.05% |
| 5 years (2019-04-25) | 1.76% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the GlaxoSmithKline P/E ratio, PEG ratio and EBITDA
GlaxoSmithKline's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, GlaxoSmithKline stocks trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0866. A PEG ratio close to 1 can be interpreted as meaning shares offer reasonable value for the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $10.3 billion.
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.